Opioid therapy for chronic noncancer pain: Practice guidelines for initiation and maintenance of therapy

Minerva Anestesiologica

Volumn 71, Issue 7-8, 2005, Pages 425-433

  Coluzzi, Flaminia ^a,c   Pappagallo, M ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c NONE   (Italy)

Author keywords

Addiction; Chronic non malignant pain; Drug taking aberrant behaviors; Opioids; Physical dependence; Pseudotolerance; Tolerance

Indexed keywords

17 METHYLNALTREXONE; ACETYLSALICYLIC ACID; ALVIMOPAN; ANALGESIC AGENT; CODEINE; DEXAMPHETAMINE; DEXTROMETHORPHAN; DEXTROPROPOXYPHENE; DOCUSATE SODIUM; FENTANYL; HYDROCODONE; HYDROMORPHONE; IBUPROFEN; KETAMINE; LACTULOSE; LEVORPHANOL; MEMANTINE; METHADONE; METHYLPHENIDATE; MODAFINIL; MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; OXYCODONE; PARACETAMOL; PETHIDINE; TESTOSTERONE; UNINDEXED DRUG;

ADDICTION; ANALGESIA; ANOREXIA; ARTICLE; BEHAVIOR DISORDER; BLOATING; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DAILY LIFE ACTIVITY; DELIRIUM; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DROWSINESS; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MISUSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DYSPHORIA; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; HYDRATION; HYPERREFLEXIA; HYPOGONADISM; MAINTENANCE THERAPY; MYOCLONUS; NARCOTIC DEPENDENCE; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NONHUMAN; PATIENT ASSESSMENT; PATIENT CARE; PATIENT CONTROLLED ANALGESIA; PATIENT EDUCATION; PATIENT SELECTION; PRACTICE GUIDELINE; QUALITY OF LIFE; RESPIRATION DEPRESSION; SEDATION; SEIZURE; SOMNOLENCE; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ANALGESICS, OPIOID; CHRONIC DISEASE; DRUG TOLERANCE; HUMANS; MENTAL DISORDERS; OPIOID-RELATED DISORDERS; PAIN;

EID: 33745306870     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Chevlen E. Opioids: a review. Curr Pain Headache Rep 2003;7:15-23.
2. Pasternak GW. Opioid pharmacology. In: Pappagallo M, editor. The neurological basis of pain. New York: McGraw Hill; 2004.p.61-70.
3. Arkinstall W, Sandler A, Goughnour B, Babul N, Harsany Z, Darke A. Efficacy of controlled-release codeine in chronic non-malignant pain. Pain 1995;62: 169-78.
4. Peloso PM, Bellamy N, Bensen W, Thomson GT, Harsanyi Z, Babul N et al. Double blind randomized placebo controlled trial of controlled release codeine in the treatment of osteoarthritis of the hip and knee. J Rheumatol 2000;27:764-71.
5. Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ et al. Around-the-clock controlled release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000;160:853-60.
6. Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Shi M et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal anti-inflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999;26:862-9.
7. Caldwell JR, Rapoport RJ, Davis JC, Offenberg HL, Marker HW, Roth SH et al. J Pain Symptom Manage 2002;23:278-91.
8. Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322: 1154-8.
9. Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer backpain. A randomized prospective study. Spine 1998;23:2591-600.
10. Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet 1996;347:143-7.
11. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
12. Dellimijn P, Vanneste JA. Randomized double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997;349:753-8.
13. Raja S, Haythornthwaite J, Pappagallo M, Clark MR, Travison TG, Sabeen S et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized-placebo controlled trial. Neurology 2002;59:1015-21.
14. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348: 1223-32.
15. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991;41:024-8.
16. Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000;14:65-70.
17. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003;60:927-34.
18. Lussier D, Pappagallo M. 10 most commonly asked questions about the use of opioids for chronic pain. Neurologist 2004;10:221-4.
19. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842-6.
20. Sindrup SH, Madsen C, Brosen K, Jensen TS. The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clin Pharmacol Ther 1999; 66:636-41.
21. Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage 1998;15: 185-94.
22. Mercadante S, Radbruch L, Caraceni A, Chemy N, Kaasa S, Nauck F et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94:832-9.
23. Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. Am J Ther 2002;9:53-68.
24. Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 2004;20:1419-28.
25. Taylor WF, Finkel AG, Robertson KR, Anderson AC, Toomey TC, Abashian SA et al. Methadone in the treatment of chronic nonmalignant pain: a 2-year follow-up. Pain Med 2000;13:254-9.
26. Pappagallo M, Heinberg LJ. Ethical issues in the management of chronic nonmalignant pain. Semin Neurol. 1997;17:203-11.
27. Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain 2000;16(2 Suppl):S73-9.
28. Freedman GM. Chronic pain. Clinical management of common causes of geriatric pain. Geriatrics 2002;57: 36-41.
29. Adunsky A, Levy R, Heim M, Mizrahi E, Arad M. Meperidine analgesia and delirium in aged hip fracture patients. Arch Gerontol Geriatr 2002;35:253-9.
30. Desai AK, Chibnall JT. Propoxyphene use in the elderly. J Am Geriatr Soc 2004;52:1227.
31. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002; 18(4 Suppl):S3-13.
32. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93.
33. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 2003;2:1026-48.
34. Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage 2002;24: 71-90.
35. Stephenson J. Methylnaltrexone reverses opioid-induced constipation. Lancet Oncol 2002;3:202.
36. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63:649-71.
37. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 2004;361:192-5.
38. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002;23:48-53.
39. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231-56.
40. Morrison RS, Magaziner J, Gilbert M, Koval KJ, McLaughlin MA, Orosz G et al. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol A Biol Sci Med Sci 2003;58:76-81.
41. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 2004;100:851-8.
42. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002;3:377-84.
43. Portenoy RK. Tolerance to opioid analgesics: clinical aspects. Cancer Surv 1994;21:49-65.
44. Gintzler AR, Chakrabarti S. Opioid tolerance and the emergence of new opioid receptor-coupled signaling. Mol Neurobiol 2000;21:21-33.
45. Bespalov AY, Zvartau EE, Beardsley PM. Opioid-NMDA receptor interactions may clarify conditioned (associative) components of opioid analgesic tolerance. Neurosci Biobehav Rev 2001;25:343-53.
46. Liu JG, Anand KJ. Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. Brain Res Brain Res Rev 2001;38:1-19.
47. Heit HA. Addiction, physical dependence, and tolerance: precise definitions to help clinicians evaluate and treat chronic pain patients. Pain Palliat Care Pharmacother 2003;17:15-29.
48. Raith K, Hochhaus G. Drugs used in the treatment of opioid tolerance and physical dependence: a review. Int J Clin Pharmacol Ther 2004;42:191-203.
49. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996;11:203-17.
50. Weissman DE, Haddox JD. Opioid pseudoaddiction-an iatrogenic syndrome. Pain 1989;36:363-6.
51. Heit HA. The truth about pain management: the difference between a pain patient and an addicted patient. Eur J Pain 2001;5 Suppl A:27-9.
52. Przewlocki R. Opioid abuse and brain gene expression. Eur J Pharmacol 2004;500:331-49.
53. Substance Abuse and Mental Health Services Administration - SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2002 http://oas.samhsa.gov/2k2State/html/ch5.htm
54. Dunbar SA, Katz NP. Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of 20 cases. J Pain Symptom Manage 1996;11:163-71.
55. Michna E, Ross EL, Hynes WL, Nedeljkovic SS, Soumekh S, Janfaza D et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manag. 2004;28:250-8.
56. Passik SD, Kirsh KL. The need to identify predictors of aberrant drug-related behavior and addiction in patients being treated with opioids for pain. Pain Med 2003;4:186-9.
57. Passik SD, Kirsh KL, Whitcomb L, Dickerson PK, Theobald DE. Pain clinicians' rankings of aberrant drug-taking behaviors. Pain Palliat Care Pharmacother 2002;16:39-49.
58. Mitka M. Experts debate widening use of opioid drugs for chronic nonmalignant pain. JAMA 2003;289:2347-8.
59. Passik SD, Kirsh KL, Whitcomb L, Portenoy RK, Katz NP, Kleinman L et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther 2004;26:552-61.